The results mark a setback for the hypothesis that drugs like semaglutide could provide a neuroprotective effect for patients ...

The Phase III trial, testing the drug in patients whose cancers are Philadelphia chromosome-positive, will expand to the US and Europe.

AACR held an event on Capitol Hill with the NCI director and a legislator to discuss government efforts to support pediatric cancer research.

The firm is developing Lumevoq as a treatment for Leber hereditary optic neuropathy caused by mutations in the ND4 mitochondrial gene.

The agency approved the autologous CAR T-cell therapy based on data showing that around 62 percent of patients had no signs of cancer after a single infusion.